Buckley Sean D. 4
4 · Fibrocell Science, Inc. · Filed Dec 13, 2019
Insider Transaction Report
Form 4
Buckley Sean D.
See Remarks
Transactions
- Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−30,000→ 0 totalExercise: $1.78Exp: 2029-04-12→ Common Stock (30,000 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−15,000→ 0 totalExercise: $1.82Exp: 2029-08-18→ Common Stock (15,000 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−334→ 0 totalExercise: $82.35Exp: 2023-07-19→ Common Stock (334 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−4,000→ 0 totalExercise: $11.25Exp: 2027-03-16→ Common Stock (4,000 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−200→ 0 totalExercise: $232.50Exp: 2021-01-14→ Common Stock (200 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−1,000→ 0 totalExercise: $63.60Exp: 2025-04-01→ Common Stock (1,000 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−2,229→ 0 totalExercise: $11.25Exp: 2026-09-27→ Common Stock (2,229 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−5,000→ 0 totalExercise: $3.45Exp: 2028-01-25→ Common Stock (5,000 underlying)
Footnotes (1)
- [F1]Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price.